Skip to main navigation Skip to search Skip to main content

The Role of Early Pregnancy Maternal pGCD59 Levels in Predicting Neonatal Hypoglycemia - Subanalysis of the DALI Study

  • Delia Bogdanet
  • , Miguel Angel Luque-Fernandez
  • , Michelle Toth-Castillo
  • , Gernot Desoye
  • , Paula M. O'shea
  • , Fidelma P. Dunne
  • , Jose A. Halperin
  • University of Galway
  • Harvard School of Public Health
  • London School of Hygiene and Tropical Medicine
  • Harvard Medical School
  • Medical University of Graz
  • Galway University Hospital

Research output: Contribution to a Journal (Peer & Non Peer)Articlepeer-review

3 Citations (Scopus)

Abstract

Context: Neonatal hypoglycaemia (NH) is the most common metabolic problem in infants born of mothers with gestational diabetes. Plasma glycated CD59 (pGCD59) is an emerging biomarker that has shown potential in identifying women at risk of developing gestational diabetes. The aim of this study was to assess the association between early maternal levels of pGCD59 and NH. Objective: The aim of this study was to assess the association between early pregnancy maternal levels of plasma glycated CD59 (pGCD59) and neonatal hypoglycemia (NH). Methods: This is an observational study of pregnant women with a prepregnancy body mass index (BMI) greater than or equal to 29 screened for eligibility to participate in the Vitamin D and Lifestyle Intervention for Gestational Diabetes (DALI) trial. This analysis included 399 pregnancies. Levels of pGCD59 were measured in fasting maternal samples taken at the time of a 75-g, 2-hour oral glucose tolerance test performed in early pregnancy (<20 weeks). NH, the study outcome, was defined as a heel-prick capillary glucose level of less than 2.6 mmol/L within 48hours of delivery. Results: We identified 30 infants with NH. Maternal levels of pGCD59 in early pregnancy were positively associated with the prevalence of NH (one-way analysis of variance, P<.001). The odds of NH were higher in infants from mothers in tertile 3 of pGCD59 levels compared to those from mothers in tertile 1 (odds ratio [OR]: 2.41; 95% CI, 1.03-5.63). However, this was attenuated when adjusted for maternal BMI (OR: 2.28; 95% CI, 0.96-5.43). The cross-validated area under the curve (AUC) was 0.64 (95% CI, 0.54-0.74), and adjusted for maternal BMI, age, and ethnicity, the AUC was 0.70 (95% CI, 0.56-0.78). Conclusion: Although pGCD59 levels in early pregnancy in women with BMI greater than or equal to 29 are associated with NH, our results indicate that this biomarker by itself is only a fair predictor of NH.

Original languageEnglish
Pages (from-to)E4311-E4319
JournalJournal of Clinical Endocrinology and Metabolism
Volume107
Issue number11
DOIs
Publication statusPublished - 1 Nov 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • biomarkers
  • epidemiology
  • glycation
  • neonatal hypoglycemia
  • prediction

Fingerprint

Dive into the research topics of 'The Role of Early Pregnancy Maternal pGCD59 Levels in Predicting Neonatal Hypoglycemia - Subanalysis of the DALI Study'. Together they form a unique fingerprint.

Cite this